the aid library

LIST OPTIONS

Filter

7648

Selecting digital contact tracing and quarantine tools for COVID-19 : guiding principles and considerations for a stepwise approach

World Health Organization WHO, Western Pacific Region (2020) CC

Contact tracing is a key component of the COVID-19 response, particularly as societies begin to lift non-pharmaceutical interventions. However, it is a time-consuming and resource-intensive effort that depends on a trained ... motivated workforce. Emergent digital contact tracing and quarantine (‎DCTQ)‎ tools offer the potential to complement and strengthen conventional contact tracing initiatives on an unprecedented scale. Despite their visibility throughout the pandemic more

External Link

Case characteristics, resource use, and outcomes of 10021 patients with COVID-19 admitted to 920 German hospitals: an observational study

Karagiannidis, C.; et al. (2020) C1

DOI:https://doi.org/10.1016/S2213-2600(20)30316-7 The Lancet Respiratory Medicine

External Link

Managing stress and anger — COVID-19

Hesperian (2020) CC

Being away from our regular routines and the people we love can be hard. Lost income, crowded living spaces, violence, fear, uncertainty, and living with depression or other mental health problems c... more

Download (156)

View PDF (159)

COVID-19 Vaccination, Country Readiness and Delivery: Supply and Logistics Guidance
recommended

World Health Organization WHO; UNICEF (2020) C_WHO

Working Document Nov. 2020 The COVAX Supply and Logistics workstream lead by UNICEF, Gavi and WHO have released a working copy of the COVID-19 Vaccination, Country Readiness & Delivery: Supply ... Logistics Guidance. Countries might find this Guide useful when developing and strengthening their supply chain strategies to receive, store, distribute and manage the COVID-19 vaccines and their ancillary products, in line with their national deployment and vaccination plan (NDVP). The document also provides links to the different tools and resources to aid countries in performing assessment, planning and capacity-building activities. more

Download (165)

View PDF (228)

Baseline Study Report Female Genital Mutilation/Cutting and Child Marriage among the Rendille, Maasai, Pokot, Samburu and Somali Communities in Kenya

United Nations Children’s Fund (UNICEF) (2017) C_UNICEF

In recognition that Female Genital Mutilation (FGM) is not only a harmful practice but a violation of human rights, Kenya has adopted a robust legal framework. The country has ratified several international legal instruments that have become part of the Kenyan law as provided for in Article 2 of the... more

Download (252)

View PDF (192)

Disease Surveillance, Emergency Preparedness and Response in Eastern and Southern Africa

World Bank, et al. (2021) CC

A Situational Assessment and Five-YearAction Plan for the Africa CDC Strengthening Regional Public Health Institutions and Capacity for Surveillance and... more

Download (107)

View PDF (137)

Social and Economic Impact of COVID-19

E. Levy Yeyati; F. Filippini The Independent Panel (2021) CC

Background paper 13 The Independent Panel for Pandemic Preparedness and Response May 2021

Download (129)

View PDF (184)

Statement of guidance and recommendations to African Union Member States on the epidemic modelling of the COVID-19 pandemic

African Union; Africa CDC Centres for Disease Control and Prevention (2021) C1

Many African countries were amongst the most rapid to respond to the emerging threat of COVID-19, implementing large-scale interventions at very early stages of their epidemic. As demonstrated in this document using very simple models, this rapid mobilization ... timeliness of implementing control measures is likely to be an important determinant of their success. Indeed, as these measures were relaxed, subsequent waves of disease have been observed in many countries including South Africa, Kenya, Tunisia, Morocco, Sudan and the Democratic Republic of Congo (DRC) where such waves have severely impacted the health system by straining the supply of oxygen and ICU beds and inflicting a heavy toll on healthcare workers, often necessitating the re-imposition of control measures. more

Download (117)

View PDF (160)

FAQs on COVID-19 Vaccines and Vaccination Program

Ministry of Health& Family Welfare, Goverment of India (2021) CC

Download (87)

View PDF (123)

Coadministration of seasonal inactivated influenza and COVID-19 vaccines

World Health Organization WHO (2021) CC

Vaccination programmes against COVID-19 and seasonal influenza are currently being implemented in parallel in many countries. Administration of both vaccines during the same visit has potential advantages. This document presents the evidence related... more

Download (162)

View PDF (234)

Tracking progress on food and agriculture-related SDG indicators 2021

Food and Agriculture Organization of the United Nations (2021) C2

Tracking progress on food and agriculture-related SDG indicators 2021 - Food and Agriculture Organization of the United Nations

Download (160)

View PDF (279)

NCDs and climate change: Shared opportunities for action

NCD Alliance (2016) CC

The policy brief focuses on four key areas for intervention - air pollution, energy, transport and food systems. Air pollution causes 7 million deaths annually, and is a leading cause of both NCDs <... climate change, thus all interventions to reduce air pollution have a positive impact on both human and planetary health. In the energy sector, transition from fossil fuels to renewable energy is if vital importance to improving health, with mortality rates due to coal-generated electricity 1,000 times higher than for wind-generated electricity. Promoting active transport such as walking and cycling in place of motorised transport has the dual benefit of reducing both air pollution and physical activity. Livestock production alone accounts for 18% of greenhouse gas emissions, with added emissions from food which are highly process and transported over long distances, and thus locally sourced plant based diets both prevent NCDs and promote human and planetary health. more

Download (156)

View PDF (226)

Public health and climate change adaptation policies in the European Union

World Health Organization WHO (2017) C_WHO

Risk communication and community engagement: a compendium of case studies in times of COVID-19

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

This collection of case studies on risk communication and community engagement (‎RCCE)‎ from 18 different country/area level public health partners in the WHO European Region provides evidence of numerous results achieved ... lessons learned since the start of the COVID-19 pandemic. RCCE has not traditionally been an area where evidence of challenges and solutions was documented. With this compendium, we wanted to collect and share this evidence to support decision-making in this area of work. more

Download (135)

View PDF (206)

Preparedness for cyclones, tropical storms, tornadoes, floods and earthquakes during the COVID-19 pandemic

World Health Organisation (WHO) (2023) C_WHO

The WHO health advisory provides guidance to countries on adapting all existing preparedness and response plans and procedures for natural hazards such as cyclones, tropical storms, tornadoes, flood... more

Download (290)

View PDF (386)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more